Modeling the Influence of Extrapyramidal Signs on the Progression of Alzheimer's Disease by Stern, Yaakov et al.
Modeling the Influence of Extrapyramidal Signs
on the Progression of Alzheimer Disease
Yaakov Stern, PhD; Xinhua Liu, PhD; Marilyn Albert, PhD; Jason Brandt, PhD; Diane M. Jacobs, PhD;
Caridad Del Castillo-Castaneda; Karen Marder, MD, MPH; Karen Bell, MD; Mary Sano, PhD; Fred Bylsma, PhD
Objective: To determine how the advent of extrapy-
ramidal signs influences the progression of Alzheimer
disease as measured by standard clinical measures.
Design: We applied growth curve models to prospec-
tive data to characterize patients' cognitive and func-
tional changes over time. To detect changes in disease
course related to extrapyramidal signs, their onset was
treated as a time-dependent covariate.
Setting: Three research medical centers.
Participants: Patients (n=217) with probable Alzhei-
mer disease.
Intervention: Patients were followed up semiannu-
ally for 5 years.
Main Outcome Measures: Scores on the modified
Mini-Mental State Examination and measures ofbasic and
instrumental activities of daily living from the Blessed De-
mentia Rating Scale.
Results: For basic and instrumental activities of daily
living, disease course was more rapid once extra-
pyramidal signs developed. Decline in the modified
Mini-Mental State Examination score was greater at
the time the signs developed, but not at subsequent
visits.
Conclusions: The point at which extrapyramidal
signs emerge is associated with measurable accelera-
tion in the progression of Alzheimer disease. This may
in part explain why extrapyramidal signs are associ-
ated with a poorer prognosis. The differential influ-
ence of extrapyramidal signs on cognitive and func-
tional measures suggests that the pathological changes
underlying these disease features may vary.
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SEVERAL STUDIES1"6 have dem¬onstrated that the presence ofextrapyramidal signs (EPS) ina patient with Alzheimer dis¬ease (AD) is associated with
more rapid progression to disease mile¬
stones, including specific scores on tests
of cognition and activities of daily living(ADL), nursing home admission, and
death. In a recent study,1 we also evalu¬
ated the predictive value of the presence
of EPS for the rate of disease progression
as assessed by the slope of mental status
or functional assessment scores. For both
of these measures, we found that the pres¬
ence of EPS at the initial visit was associ¬
ated with more rapid decline.
The present study addressed 2
issues associated with these observa¬
tions. First, most patients develop EPS
at some point in the disease.7 It is of
interest then to understand if and how
the course of the disease is changed by
the onset ofEPS. Second, our initial analy-
ses investigated the relationship between
linear estimates of rate of disease progres¬
sion and EPS.1 It has become clear that
change in scores over time in instru¬
ments that assess AD severity is not lin¬
ear.8"1 ' Itwould be valuable to evaluate this
relationship usingmore appropriate mod¬
els of AD progression.
To address these issues, we used a
recently developed method that extends
nonlinear growth curve models12 to
characterize the changes in prospec¬
tively collected data.10 This modeling
approach is flexible in that it determinesthe "shape" of the curve that best fits
the data. We previously used this ap¬
proach to compare disease progression.
See Subjects, Materials, and
Methods on next page
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All subjects were participants in the Predictors Study,13 a
multisite, longitudinal study of disease course in AD. Two
hundred thirty-six patients with probable AD were re¬
cruited into the study at 3 sites, Columbia-Presbyterian
Medical Center, New York, NY, Johns Hopkins Hospital,
Baltimore, Md, and Massachusetts General Hospital, Bos¬
ton. Details of inclusion and exclusion criteria and recruit¬
ment methods have been previously described.13 Briefly, all
patients were required to meet the National Institute ofNeu¬
rological Disorders and Stroke-Alzheimer's Disease and Re¬
lated Disorders Association criteria14 for probable AD. To
ensure that severity of dementia was mild at study entry,
all patients were required to have a modified Mini-Mental
State Examination (MMSE) score of 30 or above (corre¬
sponding to approximately 16 on the standard MMSE). Pa¬
tients with small subcortical lesions that were clinically and
historically silent were included. However, patients with
cortical lesions of any size or location or with focal corti¬
cal atrophy in a specific vascular distribution were ex¬
cluded.
PROCEDURES
All patients were evaluated at 6-month intervals. Cogni¬
tive function was examined using the modified MMSE.15
This instrument includes all items from the standard
MMSE16 and also includes the Wechsler Adult Intelli¬
gence Scale Digit Span subtest17 and additional attention
and calculation, general knowledge, language, and con¬
struction items. The maximum score on this test is 57. This
is a valid and reliable instrument18 that is brief yet infor¬
mative.
Functional capacity was rated using the Blessed De¬
mentia Rating Scale (part 1) " using a structured interview
to guide and standardize administration. A previous fac¬
tor analysis of this instrument yielded 4 factors with a dis¬
tinct pattern of progression.20 In the current analyses, we
concentrated on 2 factors that reflect 2 specific types ofADL.
Instrumental ADL (IADL) were assessed by items 1 through
7, which address functions such as orientation, perform¬
ing chores, and remembering lists. These items are tradi¬
tionally scored on a 3-point scale as absent (0), partially
impaired (0.5), or fully impaired (1). To simplify analysis,
this 3-point scale was recoded and ranged from 0 to 2. Thus,
the maximum score for IADL was 14. Basic ADL (BADL)
were measured by 3 items: eating, dressing, and toileting.
These are rated on a 4-point scale ranging from 0 to 3. Thus,
the maximum BADL score was 9. For both ADL domains,
a higher score denotes more impairment.
Selected items from the Unified Parkinson's Disease
Rating Scale21 were used to rate EPS. The reliability of the
scale for use in probable AD has been established.22 Hypo-phonia, masked faces, resting tremor, rigidity (neck and
each limb), bradykinesia or hypokinesia, and posture and
gait abnormalities were rated as absent, slight, mild-
moderate, marked, or severe (see Richards et al22 for com¬
plete form). For all analyses, patients who had at least 1
sign rated as mild-moderate were considered to have EPS.
We used this criterion since ratings of EPS of this severity
are more reliable and are likely to be noted by a clini¬
cian.22 The EPS were coded as idiopathic, probably in¬
duced by current neuroleptic medication, or possibly in¬
duced by previous neuroleptic medication. Our analyses
focused on non-drug induced EPS. If a patient's EPS were
possibly or probably drug induced when they were first
noted, then that patient's observations were not included
in the statistical analyses.
STATISTICAL ANALYSIS
The mathematical properties of the modeling approach have
been described.10 It applies the principles of growth mod¬
els, which can be specified by an equation that assumes that
the growth rate, or change in a test score, is a function of
the present score. The modeling procedure begins by cal¬
culating changes in test scores between all adjacent 6-month
visits for each subject. Thus, only patients with at least 2
consecutive scores on a measure can be included in the cal¬
culations. The goal is to characterize the conditional aver¬
age change in a score based on the current score, E(Yk+1
—
Yfe/
Yfe), where Yk represents a test score at time fe, Yfe+1—Yk is
the change in the next interval, and E denotes the expec¬
tation operation. We model the conditional average change
with a function in a form similar to the von Bertanalffy
growth curve model,12 which unifies various types of mod¬
els including monomolecular, logistic, and Gompertz. The
values of the model parameters determine the shape of the
model and the point of maximal change in scores (if one
exists). A quasi-likelihood approach is used to estimate
model parameters to best fit the data. The procedure mini¬
mizes the mean square error of prediction of changes in
test scores. The 95% confidence intervals can be calcu¬
lated for the various model parameters as well.
In the present analyses we applied an extension of the
modeling technique that allows for the incorporation of the
onset of EPS as a time-dependent covariate. Thus, we could
model how progression changes when the patient devel¬
ops EPS. The modeling procedure was applied separately
to the modified MMSE total score and the 2 ADL factors.
To visually display the consequences ofdeveloping EPS
for the progression of each measure, we used 2 ap¬
proaches. First, we used the model to generate the pre¬
dicted change in a score over the next 6 months as a func¬
tion of each value of the current test score in patients with
and without EPS. These were graphed and compared with
the empirically observed changes in scores. Second, we mod¬
eled the progression in a test score over time, given a spe¬
cific starting score. In this case, the starting score gener¬
ates a prediction of the score at the next time interval, and
this process is repeated until the score reaches its upper or
lower bound. The generated curve is therefore a general¬
ized representation of the progression of the test score over
time. The procedure uses all patient data to derive a model
progression of a test score from its highest to its lowest point
even though no individual patient's data may span this en¬
tire range. Therefore, the period represented in the graphed
model of progression is often longer than the time any in¬
dividual patient is followed up.
To demonstrate the modeled impact of the onset of
EPS, we graphed progression in a hypothetical patient who
never develops EPS. We then graphed progression when
EPS developed at 2 different points in time.
Figure 1. Based on the growth curve model, predicted average change of
modified Mini-Mental State Examination (MMSE) scores over a 6-month
interval as a function of the current score. Two predictions are presented
for each score, one for the interval in which extrapyramidal signs (EPS)
are first noted and another for all other intervals.
as assessed by the modified Mini-Mental State Exami¬
nation and by measures of instrumental and basic
ADL.11 The modeling technique also allows the incor¬
poration of subgroups or time-dependent covariates.
In the present analyses, we used our modeling
approach to investigate how the onset of EPS may
influence the course of AD by treating the onset of
EPS as a time-dependent covariate.
RESULTS
MODIFIED MMSE PROGRESSION
Of 217 patients with data amenable to the analysis, 56
patients developed EPS at some point during their follow-
up. The modified MMSE score at the time EPS occurred
ranged from 14 to 48 with a mean of 31.9 (SD=7.98).
We calculated the mean of the empirically ob¬
served changes over a 6-month interval for each modi¬
fied MMSE score. Overall, there was no difference in these
changes in scores in patients with and without EPS. Ob¬
servation of the data suggested that the change in modi¬
fied MMSE score was increased at the interval in which
EPS developed.
In the modeling procedure, the introduction of
the status of EPS as a time-dependent covariate pro¬
duced a statistically significant increase in the accu¬
racy of the model. However, the contribution of EPS
to the model occurred only at the point that EPS
develop; the predicted change in the modified MMSE
score at any other interval remained the same whether




Yk/Yh,Xk) = -0.1687Yfe log(57/YK)
-0.0882Xfe (57-Y(!)
In this equation, Yk is the modified MMSE score at
time k. Xk equals 1 if EPS developed during the k time
interval; Xk equals 0 if there was no change in status of
the EPS between times k and fe4-l. Thus, for any
patient Xk can equal 1 only once during the progres-
Figure 2. A time series of modified Mini-Mental State Examination(MMSE) scores generated by the growth curve model, beginning with an
initial score of 56. EPS indicates extrapyramidal signs.
sion of the disease. Substituting a current modified
MMSE score for Yk and the appropriate value for Xk in
the equation generates a prediction of the amount of
decline in the modified MMSE score over the subse¬
quent 6-month interval. This model indicates that the
initial occurrence of EPS result in accelerated decline in
modified MMSE in that interval. In addition, the amount
of additional decline associated with the advent of EPS is
larger when the modified MMSE score is lower. This is
illustrated in Figure 1, which plots the model's predic¬
tions of the change in modified MMSE score over the
next 6-month interval based on the current modified
MMSE score. Two predicted changes are plotted, one
that applies only to the interval in which EPS are first
noted, and another that applies to all other study inter¬
vals. Note that the additional decline associated with the
onset of EPS is greater when the modified MMSE score
is lower.
Figure 2 illustrates 3 hypothetical patients, each
beginning with a modified MMSE score of 56. The
first patient never develops EPS and exhibits the pat¬
tern of progression for the modified MMSE score in
AD that we have described previously. The other 2
patients develop EPS at intervals 17 and 28, respec¬
tively. There is a larger change in the modified MMSE
score at the interval that EPS develop. However, sub¬
sequent rate of decline in modified MMSE score is not
affected.
IADL PROGRESSION
The observed average change in IADL score over the next
6-month interval was calculated separately for each ini¬
tial IADL score. These changes differed significantly in
patients with and without EPS, as illustrated in Figure 3.
In almost every case, observed change was greater in pa¬
tients with EPS.
At the time EPS were first noted, IADL scores ranged
from 0 to 14, with a mean score of 8.4 (SD=2.87). In the
modeling procedure, the introduction of the onset of EPS
as a time-dependent covariate yielded a significant in-
Figure 3. For each instrumental activities of daily living (IADL) score, thepredicted and the observed average change in score over the next 6-month
interval In patients with and without extrapyramidal signs (EPS).
Figure 4. A time series of instrumental activities of daily living (IADL)
scores generated by the growth curve model, beginning with an initial
score of 1. EPS indicate extrapyramidal signs.
crease in the accuracy of the model. In contrast to the
modified MMSE, the rate of progression of IADL scores
differed for all intervals in which EPS were present. The
derived growth curve function was as follows:
E(Yfe+1-Yfe/Yfe,Xfe) = (14-Yfe)(0.12664-0.0874Xfe)
Again, Yk is in the IADL score at time k. Xk equals 1 if
EPS are present at time k; Xk equals 0 if EPS are not
present. Substituting the current IADL value for Yk
and the appropriate value for Xk into the equation
yields a prediction of the change in IADL scores over
the next 6-month interval. This model indicates that
once EPS develop, the rate of change in IADL scores is
increased at all subsequent visits. The accelerated rate
of change associated with EPS becomes more marked
as IADL scores increase. The model-based predicted
change in IADL score associated with each current
IADL score for patients with and without EPS is plot¬
ted in Figure 3.
Figure 4 illustrates 3 hypothetical patients, each
beginning with an IADL score of 1. The first patient
Figure 5. For each basic activities of daily living (BADL) score, the
predicted and the observed average change in score over the next 6-month
interval in patients with and without extrapyramidal signs (EPS).
Figure 6. A time series of basic activities of daily living (BADL) scores
generated by the growth curve model, beginning with an initial score of 1.
EPS indicate extrapyramidal signs.
never develops EPS and exhibits the typical pattern of
progression for IADL scores in AD that we have
described previously.10 The other 2 patients develop
EPS at intervals 4 and 9, respectively. Note that the
progression of IADL scores is altered in the presence
of EPS.
BADL PROGRESSION
At the time of onset of EPS, BADL scores ranged from
0 to 9, but the mean score was 1.6 (SD = 1.97) and
the model score was 0. We separately calculated the
mean of the empirically observed changes over a
6-month interval for each initial BADL score. These
changes differed significantly in patients with and
without EPS, as illustrated in Figure 5. Again,
patients with EPS had greater changes in scores than
those without EPS.
In the modeling procedure, the introduction of
the onset of EPS as a time-dependent covariate yielded
a significant increase in the accuracy of the model. As
with IADL scores, the rate of progression of BADL
scores differed for all intervals in which EPS were pres¬
ent. The derived growth curve function was as follows:
E(Yfe+1-Yfe/Yfe<9,Xfc)=0.30864-0.3745X(!
E(Yk+l-Yk/Yk=9,Xk)=0
Again Yk indicates the BADL score at time k. Xk equals 1
if EPS are present at time k and 0 if they are not. Once
the BADL score reaches its maximum of 9, it does not
change over time. The model-based predicted change in
BADL score associated with each current BADL score for
patients with and without EPS is shown in Figure 5.
Figure 6 illustrates 3 hypothetical patients, each
beginning with a BADL score of 1. The first patient never
develops EPS and exhibits the typical linear progression
for BADL score in AD that we have described previ¬
ously. The other 2 patients develop EPS at intervals 6 and
14, respectively. Note that the progression ofBADL scores
is altered in the presence of EPS.
COMMENT
While it has been established that the presence of EPS
has prognostic implications for the rapidity of the
course of AD, it has not been clear whether or how
disease progression actually changes when EPS
develop. The present analyses suggest that there is a
change in disease progression that coincides with the
onset of EPS.
It is notable that the clinical detection of EPS was
associated with changes in the rapidity of disease pro¬
gression. Typically, EPS are viewed as the culmination
of an insidious degenerative process. For example, in
Parkinson disease it has been estimated that EPS do
not emerge until dopaminergic input to the basal gan¬
glia is about 80% depleted.23 While the neuropatho¬
logical cause of EPS in AD has not been established, it
is equally likely that the causal pathological changes
are slowly progressive and could influence the course
of AD even before EPS emerge. However, the present
analyses indicate that the onset of clinically appre¬
ciable EPS has direct consequences for progression.
This suggests that the pathological changes underlying
EPS must reach a certain level of severity before they
markedly influence disease course.
For measures of IADL and BADL, the clinical de¬
tection of EPS was associated with a persistent change
in the course of the disease: a greater change in scores
over each subsequent 6-month interval. This was not the
case for the modified MMSE, where there was an accen¬
tuated decline in the modified MMSE score only in the
interval in which EPS emerged. It is not clear why the
effect of EPS should differ between the ADL measures
and the modified MMSE. We have already reported that
the shape of the progression curve differs in each of the
3 measures.11 We hypothesized that while these differ¬
ences may to some degree be a function of psychomet¬
ric properties of the tests, they probably also represent
real differences in how various facets of the disease
progress over time. The differential effect of the onset of
EPS on ADL and modified MMSE progression lends some
support to the latter concept.
Extrapyramidal signs are an important feature of
AD. Two studies24·25 have demonstrated that the pres¬
ence of subtle EPS in nondemented elderly people is
actually a risk factor for incident AD. One actuarial
study7 suggested that, with careful observation, EPS
are eventually noted in all patients with AD. Our
group and others have demonstrated that the presence
of EPS is associated with a poorer prognosis and more
rapid disease progression. Patterns of performance on
neuropsychological tests differ in patients with AD
with and without EPS26,2'; those with EPS appear to
have the typical pattern of cognitive change, along
with an overlay of additional cognitive deficit.27
While pathological determinants of EPS in AD are
unclear, most likely several processes are implicated.
One postmortem study28 of patients with probable AD
and EPS indicated that neuropathological changes of
AD and Parkinson disease, including degeneration in
the substantia nigra and Lewy bodies, may coexist.
Several investigators26·2930 have suggested a Lewy body
variant of AD, characterized by some unique cognitive
and behavioral changes and the presence of EPS. How¬
ever, we have noted clinically that not all patients with
AD and EPS meet other clinical criteria for the Lewy
body variant. In addition, the majority of the patients
in the present study who developed EPS at some point
before death and underwent autopsy did not have cor¬
tical or subcortical Lewy bodies. We therefore propose
that for the majority of patients the occurrence of EPS
may represent a developmental stage of AD and not a
subgroup or disease variant. Data from a previous
study7 support the idea that EPS, myoclonus, and psy¬
chosis are typical clinical features that can emerge at
different stages of disease. We compared cumulative
risk functions for putative predictors and found that in
the early stages of AD, EPS and psychosis were more
likely to develop than myoclonus. As AD progressed,
the risk of developing myoclonus became as great as
that of developing the other 2 signs. More than 1 sign
often coexisted in the same patient. Thus, the various
clinical signs have different probabilities of emerging
at different points in the disease. Clinical heterogene¬
ity might then be viewed as reflecting variation in this
probability distribution. Whenever EPS emerge, they
are associated with a poorer prognosis.
In summary, the onset ofEPS is associated with more
rapid functional decline and with an abrupt decline in
intellectual function. These changes may elucidate the
poor prognosis associated with EPS in AD.
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